Dentsply Sirona Q4 Beats Estimates with Revenue of $983M and Non-GAAP EPS of $0.46, FY23 Outlook Positive.

Trending News ☀️

The positive outlook of Dentsply Sirona ($NASDAQ:XRAY) is based on the company’s underlying fundamentals, which include a comprehensive portfolio of dental solutions, continued investments in its digital platform and product innovation, and a strong track record in growth. Additionally, the company will continue to focus on strengthening its balance sheet and cash flow generation to support further investments in its business. Overall, the results from this quarter demonstrate that Dentsply Sirona is well positioned for future growth and success. Investors can remain optimistic about the company’s prospects for FY2023 and beyond.

Price History

O n T u e s d a y , D e n t s p l y S i r o n a r e p o r t e d t h e i r Q 4 e a r n i n g s a n d b e a t a n a l y s t s ’ e x p e c t a t i o n s w i t h a r e v e n u e o f $ 9 8 3 m i l l i o n a n d n o n – G A A P e a r n i n g s – p e r – s h a r e o f $ 0 . 4 6 . T h i s c a u s e d i t s s t o c k t o o p e n a t $ 3 8 . 2 a n d c l o s e a t $ 3 8 . 1 , r e p r e s e n t i n g a s u r g e o f 1 0 . 2 % f r o m i t s p r i o r c l o s i n g p r i c e o f $ 3 4 . 6 . T h e c o m p a n y p r o v i d e d a n u p b e a t o u t l o o k f o r t h e u p c o m i n g f i s c a l y e a r o f 2 3 , w h i c h f u r t h e r f u e l e d i t s s t o c k p r i c e p e r f o r m a n c e . F o r t h e q u a r t e r e n d i n g D e c e m b e r 3 1 s t , D e n t s p l y S i r o n a ‘ s r e v e n u e w a s u p b y 6 .

6 % , i n c o m p a r i s o n t o t h e s a m e p e r i o d l a s t y e a r . T h e c o m p a n y ‘ s n o n – G A A P e a r n i n g s – p e r – s h a r e c a m e i n a t $ 0 . 4 6 , e x c e e d i n g t h e e x p e c t e d e s t i m a t e s o f $ 0 . 3 9 . 1 % . 6 6 t o $ 1 . C o n s e q u e n t l y , a n a l y s t s e x p e c t t h e c o m p a n y ‘ s s t o c k t o c o n t i n u e o u t p e r f o r m i n g t h e m a r k e t a n d r e m a i n u p b e a t t h r o u g h o u t t h e y e a r. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Dentsply Sirona. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Dentsply Sirona. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Dentsply Sirona. More…

Key Ratios Snapshot

Some of the financial key ratios for Dentsply Sirona are shown below. More…

Analysis

After performing a thorough risk assessment of DENTSPLY SIRONA, we have identified three different risk warnings from their income statement, balance sheet, and non-financial statements. We are confident that our detailed analysis will provide investors with the necessary information to make informed decisions. We invite all investors to take advantage of our analysis and register with us to view more in-depth information. Our platform uses the latest technology and data to offer timely and comprehensive insight into a company’s performance and future prospects. We provide an extensive risk rating which gives investors a better understanding of their potential returns and risks associated with the company. With our risk analysis, investors can make sound investment decisions that can be beneficial in the long-term. More…

Peers

In the competitive world of dental equipment manufacturers, Dentsply Sirona Inc. has held its own against some tough competitors. Edwards Lifesciences Corp, Escalon Medical Corp, and Medistim ASA are all companies that produce dental equipment and supplies that compete with Dentsply Sirona Inc.

– Edwards Lifesciences Corp ($NYSE:EW)

Edwards Lifesciences Corp is a medical technology company that specializes in products and technologies for the treatment of cardiovascular diseases. The company’s market capitalization is $45.45 billion as of 2022, and its return on equity is 18.9%. Edwards Lifesciences is headquartered in Irvine, California, and has operations in more than 75 countries worldwide.

– Escalon Medical Corp ($OTCPK:ESMC)

Escalon Medical Corp is a medical device company that manufactures and markets products for the ophthalmology, optometry, and veterinary markets worldwide. It has a market cap of 800.11k as of 2022 and a return on equity of 1.57%. The company’s products include ophthalmic surgical instruments, intraocular lenses, contact lenses, and disposables.

– Medistim ASA ($BER:MD1)

Medistim ASA is a Norwegian medical device company that develops, manufactures, and markets products for use in cardiac and vascular surgery. The company has a market capitalization of 455.95 million as of 2022 and a return on equity of 24.86%. Medistim’s products are used in a variety of procedures, including coronary artery bypass graft surgery, valve replacement surgery, and endovascular surgery. The company’s products are sold in over 50 countries worldwide.

Summary

Dentsply Sirona, a global leader in dental manufacturing, recently reported strong financial performance for the fourth quarter of its fiscal year. This pushed shares of the company higher on the day of the announcement. As such, investors may be wise to consider investing in a company with a proven track record of success.